Literature DB >> 19920845

In vivo quantification of monoamine oxidase A in baboon brain: a PET study using [(11)C]befloxatone and the multi-injection approach.

Michel Bottlaender1, Héric Valette, Jacques Delforge, Wadad Saba, Ilonka Guenther, Olivier Curet, Pascal George, Frédéric Dollé, Marie-Claude Grégoire.   

Abstract

[(11)C]befloxatone is a high-affinity, reversible, and selective radioligand for the in vivo visualization of the monoamine oxidase A (MAO-A) binding sites using positron emission tomography (PET). The multi-injection approach was used to study in baboons the interactions between the MAO-A binding sites and [(11)C]befloxatone. The model included four compartments and seven parameters. The arterial plasma concentration, corrected for metabolites, was used as input function. The experimental protocol-three injections of labeled and/or unlabeled befloxatone-allowed the evaluation of all the model parameters from a single PET experiment. In particular, the brain regional concentrations of the MAO-A binding sites (B'(max)) and the apparent in vivo befloxatone affinity (K(d)) were estimated in vivo for the first time. A high binding site density was found in almost all the brain structures (170+/-39 and 194+/-26 pmol/mL in the frontal cortex and striata, respectively, n=5). The cerebellum presented the lowest binding site density (66+/-13 pmol/mL). Apparent affinity was found to be similar in all structures (K(d)V(R)=6.4+/-1.5 nmol/L). This study is the first PET-based estimation of the B(max) of an enzyme.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19920845      PMCID: PMC2949159          DOI: 10.1038/jcbfm.2009.242

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  38 in total

Review 1.  Translational neuroimaging: positron emission tomography studies of monoamine oxidase.

Authors:  Joanna S Fowler; Jean Logan; Nora D Volkow; Gene-Jack Wang
Journal:  Mol Imaging Biol       Date:  2005 Nov-Dec       Impact factor: 3.488

2.  Monoamine oxidase inhibitors allow locomotor and rewarding responses to nicotine.

Authors:  Anne-Sophie Villégier; Lucas Salomon; Sylvie Granon; Jean-Pierre Changeux; James D Belluzzi; Frances M Leslie; Jean-Pol Tassin
Journal:  Neuropsychopharmacology       Date:  2005-12-14       Impact factor: 7.853

3.  Monoamine oxidase A rather than monoamine oxidase B inhibition increases nicotine reinforcement in rats.

Authors:  Karine Guillem; Caroline Vouillac; Marc R Azar; Loren H Parsons; George F Koob; Martine Cador; Luis Stinus
Journal:  Eur J Neurosci       Date:  2006-12       Impact factor: 3.386

Review 4.  Structural aspects of monoamine oxidase and its reversible inhibition.

Authors:  J Wouters
Journal:  Curr Med Chem       Date:  1998-04       Impact factor: 4.530

Review 5.  Contribution of monoamine oxidase (MAO) inhibition to tobacco and alcohol addiction.

Authors:  Jan van Amsterdam; Reinskje Talhout; Wim Vleeming; Antoon Opperhuizen
Journal:  Life Sci       Date:  2006-06-15       Impact factor: 5.037

6.  Clinical pharmacology of befloxatone: a brief review.

Authors:  P Rosenzweig; A Patat; O Curet; G Durrieu; C Dubruc; I Zieleniuk; E Legangneux
Journal:  J Affect Disord       Date:  1998-12       Impact factor: 4.839

7.  Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression.

Authors:  Jeffrey H Meyer; Nathalie Ginovart; Anahita Boovariwala; Sandra Sagrati; Doug Hussey; Armando Garcia; Trevor Young; Nicole Praschak-Rieder; Alan A Wilson; Sylvain Houle
Journal:  Arch Gen Psychiatry       Date:  2006-11

8.  Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.

Authors:  Nathalie Ginovart; Jeffrey H Meyer; Anahita Boovariwala; Doug Hussey; Eugenii A Rabiner; Sylvain Houle; Alan A Wilson
Journal:  J Cereb Blood Flow Metab       Date:  2006-03       Impact factor: 6.200

Review 9.  Monoamine oxidase: from genes to behavior.

Authors:  J C Shih; K Chen; M J Ridd
Journal:  Annu Rev Neurosci       Date:  1999       Impact factor: 12.449

10.  Effect of monoamine oxidase inhibition on amphetamine-evoked changes in dopamine receptor availability in the living pig: a dual tracer PET study with [11C]harmine and [11C]raclopride.

Authors:  Svend Borup Jensen; Aage Kristian Olsen; Kasper Pedersen; Paul Cumming
Journal:  Synapse       Date:  2006-06-01       Impact factor: 2.562

View more
  8 in total

1.  Quantitative PET imaging of radioligands with slow kinetics in human brain.

Authors:  Sandra M Sanabria-Bohórquez; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-06-25       Impact factor: 9.236

2.  Lower Monoamine Oxidase-A Total Distribution Volume in Impulsive and Violent Male Offenders with Antisocial Personality Disorder and High Psychopathic Traits: An [(11)C] Harmine Positron Emission Tomography Study.

Authors:  Nathan J Kolla; Brittany Matthews; Alan A Wilson; Sylvain Houle; R Michael Bagby; Paul Links; Alexander I Simpson; Amina Hussain; Jeffrey H Meyer
Journal:  Neuropsychopharmacology       Date:  2015-06-17       Impact factor: 7.853

3.  Relationship of monoamine oxidase-A distribution volume to postpartum depression and postpartum crying.

Authors:  Julia Sacher; P Vivien Rekkas; Alan A Wilson; Sylvain Houle; Leslie Romano; Jinous Hamidi; Pablo Rusjan; Ian Fan; Donna E Stewart; Jeffrey H Meyer
Journal:  Neuropsychopharmacology       Date:  2014-07-30       Impact factor: 7.853

4.  Convergent effects of acute stress and glucocorticoid exposure upon MAO-A in humans.

Authors:  Alexandra Soliman; Chinelo Udemgba; Ian Fan; Xin Xu; Laura Miler; Pablo Rusjan; Sylvain Houle; Alan A Wilson; Jens Pruessner; Xiao-Ming Ou; Jeffrey H Meyer
Journal:  J Neurosci       Date:  2012-11-28       Impact factor: 6.167

5.  Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.

Authors:  Lina Chiuccariello; Robert G Cooke; Laura Miler; Robert D Levitan; Glen B Baker; Stephen J Kish; Nathan J Kolla; Pablo M Rusjan; Sylvain Houle; Alan A Wilson; Jeffrey H Meyer
Journal:  Int J Neuropsychopharmacol       Date:  2015-08-27       Impact factor: 5.176

6.  PET imaging of brain inflammation during early epileptogenesis in a rat model of temporal lobe epilepsy.

Authors:  Stefanie Dedeurwaerdere; Paul D Callaghan; Tien Pham; Gita L Rahardjo; Halima Amhaoul; Paula Berghofer; Mitchell Quinlivan; Filomena Mattner; Christian Loc'h; Andrew Katsifis; Marie-Claude Grégoire
Journal:  EJNMMI Res       Date:  2012-11-08       Impact factor: 3.138

7.  In vivo measurement of hippocampal GABAA/cBZR density with [18F]-flumazenil PET for the study of disease progression in an animal model of temporal lobe epilepsy.

Authors:  Lucy Vivash; Marie-Claude Gregoire; Viviane Bouilleret; Alexis Berard; Catriona Wimberley; David Binns; Peter Roselt; Andrew Katsifis; Damian E Myers; Rodney J Hicks; Terence J O'Brien; Stefanie Dedeurwaerdere
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

8.  Kinetic analysis of [11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A.

Authors:  Paolo Zanotti-Fregonara; Claire Leroy; Dimitri Roumenov; Christian Trichard; Jean-Luc Martinot; Michel Bottlaender
Journal:  EJNMMI Res       Date:  2013-11-25       Impact factor: 3.138

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.